Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

Vera Therapeutics has delivered a strong 184.9% return over the past 5 years, yet its valuation checks and current market multiples point to a stock that may now be leaning expensive rather than clearly cheap. With accelerated FDA approval for Trutakna helping to reshape expectations, the question is how much of that optimism is already reflected in the price.

• The 184.9% 5 year return suggests long term holders have already seen substantial gains, which can limit upside if expectations are already high.

• The accelerated approval of Trutakna for IgA nephropathy can support growth expectations, while the need to confirm long term kidney outcomes and compete with larger rivals may weigh on how much investors are willing to pay.

• A mixed value score of 3 out of 6 points to Vera Therapeutics looking neither like an obvious bargain nor a clearly overstretched stock on the broader checks.

The stock's next move may depend on whether Vera Therapeutics' current price fairly reflects its recent approval win and the risks that still sit around execution and competition.

Vera Therapeutics delivered 74.3% returns over the last year. See how this stacks up to the rest of the Biotechs industry.

Has Vera Therapeutics Run Too Far on Book Value?

P/B is a useful check for Vera Therapeutics because it is still building its earnings profile and investors often look to the balance sheet and pipeline potential when judging value. Vera trades on a P/B of 6.1x, which is higher than both the broader biotech industry average of 2.7x and the peer group average of 8.2x.

That premium indicates that investors are already paying a higher price for Vera Therapeutics' assets and the prospects around Trutakna following its accelerated FDA approval. However, P/B does not provide information about future profitability or execution risk. With the stock priced above the sector's typical multiple, the market is assigning a richer valuation to Vera relative to many biotechs, despite the usual uncertainties around long term outcomes and competition.

On this P/B yardstick, Vera Therapeutics stock currently appears overvalued relative to these peer and industry comparisons.

See what the numbers say about this price — find out in our valuation breakdown.

The Vera Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives aim to clarify what Vera Therapeutics' current valuation implies about its future by spelling out which paths for revenue, margins and earnings would need to play out for the stock to be worth meaningfully more or less than it is today on the market. Instead of leaving you with a single output from a ratio or model, these narratives unpack the underlying assumptions so you can see and monitor the future that figure relies on, and they sit on Simply Wall St's Community page.